Cargando…
Paeonol protects against doxorubicin-induced cardiotoxicity by promoting Mfn2-mediated mitochondrial fusion through activating the PKCε-Stat3 pathway
INTRODUCTION: The anti-cancer medication doxorubicin (Dox) is largely restricted in clinical usage due to its significant cardiotoxicity. The only medication approved by the FDA for Dox-induced cardiotoxicity is dexrazoxane, while it may reduce the sensitivity of cancer cells to chemotherapy and is...
Autores principales: | Ding, Mingge, Shi, Rui, Fu, Feng, Li, Man, De, Dema, Du, Yanyan, Li, Zongfang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173194/ https://www.ncbi.nlm.nih.gov/pubmed/35842187 http://dx.doi.org/10.1016/j.jare.2022.07.002 |
Ejemplares similares
-
Mfn2-mediated mitochondrial fusion alleviates doxorubicin-induced cardiotoxicity with enhancing its anticancer activity through metabolic switch
por: Ding, Mingge, et al.
Publicado: (2022) -
Corrigendum to “Mfn2-mediated mitochondrial fusion alleviates doxorubicin-induced cardiotoxicity with enhancing its anticancer activity through metabolic switch” [Redox Biol. 52 (2022) 1–16/102311]
por: Ding, Mingge, et al.
Publicado: (2022) -
Paeonol promotes Opa1-mediated mitochondrial fusion via activating the CK2α-Stat3 pathway in diabetic cardiomyopathy
por: Liu, Chaoyang, et al.
Publicado: (2021) -
Trophoblast Stem-Cell-Derived Exosomes Alleviate Cardiotoxicity of Doxorubicin via Improving Mfn2-Mediated Mitochondrial Fusion
por: Duan, Junfeng, et al.
Publicado: (2023) -
STAT6 in mitochondrial outer membrane impairs mitochondrial fusion by inhibiting MFN2 dimerization
por: Kim, Hyunmi, et al.
Publicado: (2022)